Issues and barriers to development of clinically useful tumor markers: A development pathway proposal

Seminars in Oncology

Volumn 29, Issue 3, 2002, Pages 213-221

  Hammond, M Elizabeth H ^a   Taube, Sheila E ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b LDS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER RESEARCH; CLINICAL LABORATORY; CLINICAL PATHWAY; DISEASE MARKER; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE;

EID: 0036277226     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.32896     Document Type: Article

References (56)

1. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology
2. 1997 Update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology
3. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee
4. College of American Pathologists Conference XXXV: Solid tumor prognostic factors - Which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants
5. Design and conduct of clinical trials
6. Statistical aspects of prognostic factor studies in oncology
7. Breast cancer prognostic factors: Evaluation guidelines
8. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers
9. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
10. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy
11. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer
12. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients
13. Tissue microarrays for high-throughput molecular profiling of tumor specimens
14. Estrogen and progesterone receptor concentrations and prevalence of tumor hormonal phenotypes in older breast cancer patients
15. Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?
16. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
17. Immunohistochemical quantitation of thyrnidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy
18. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy
19. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma
20. Biomarkers for early detection of colon cancer
21. p53 alterations are associated with improved prognosis in distal colonic carcinomas
22. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
23. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer
24. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug administration-approved scoring system
25. Recommendations for HER 2 testing in the UK
26. Standardization of immunohistochemistry based on antigen retrieval technique for routine formalin fixed tissue sections
27. A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory
28. An exaltation of experts: Concerted efforts in the standardization of immunohistochemistry
29. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: Correlation with patient age, assay sensitivity, threshold value, and mammographic screening
30. Immunohistochemical detection of steroid receptors in breast cancer: A working protocol
31. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999
32. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: A basis for checklists
33. Immunocytochemical demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: Correlation with estrogen receptor assay by dextran-coated charcoal method
34. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response
35. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence
36. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests
37. Incorporating the time dimension in receiver operating characteristic curves: A case study of prostate cancer
38. Inference procedures for assessing interobserver agreement among multiple raters
39. Principles of test interpretation
40. The relationships among performance measures in the selection of diagnostic tests
41. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers
42. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer
43. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI- 2 in breast carcinomas
44. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients
45. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1
46. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
47. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
48. Study indicates utility for new breast cancer prognostic marker
49. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
50. Medical devices; classification/reclassification; restricted devices; analyte specific reagents
51. Tamoxifen for early breast cancer: An overview of the randomised trials
52. The efficacy of diagnostic imaging
53. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy